Proboxis Bio
Meeting a global need – flexible, scalable vaccines against mosquito-borne flaviviruses
Japanese encephalitis, dengue, Zika, yellow fever and West Nile virus threaten populations worldwide, placing over 4 billion people at risk. Japanese encephalitis causes about 70,000 clinical cases annually, with fatality rates of up to 30% and leaves many survivors with permanent neurological disabilities. Climate change, expanding mosquito ranges and international travel are increasing the spread of these diseases into new regions.
Proboxis Bio is addressing a critical gap in global infectious disease preparedness: the need for flexible, scalable vaccines against mosquito-borne flaviviruses. Its ISVac™ platform uses benign insect-specific viruses to develop and manufacture vaccines against multiple flaviviruses. By replacing the virus’s surface proteins with those of a disease-causing flavivirus, ISVac™ generates vaccine particles that closely resemble the target pathogen but cannot replicate in humans or other vertebrates.
Unlike single-product approaches, ISVac is designed as a reusable platform supporting multiple vaccine candidates through a shared mosquito-cell production system, manufacturing process, analytical framework, and regulatory knowledge base. Proboxis Bio says its, ISVac-JEV, has generated strong neutralising antibody responses and protected mice and pigs against Japanese encephalitis virus (JEV), providing proof-of-concept for the wider platform.
Biointelect Venturer funding for this project supports Proboxis Bio to advance scalable manufacturing and purification processes; strengthen its commercial, regulatory and intellectual property strategy; and establish the company required to advance ISVac™ platform candidates into clinical trials.
If successful, starting with a new vaccine for JEV, Proboxis Bio’s goal is to build an Australian vaccine company capable of developing a pipeline of vaccines against established and emerging flavivirus threats, strengthening sovereign manufacturing capability while contributing to a more resilient national and global health security framework.
- BV Round 1 Project: Vaccine Production Platform
- State: QLD
- Project Lead: A/Prof Jody Peters
- Project Partners:
- The University of Queensland
- School of Chemistry and Molecular Biosciences (SCMB)
- Uniquest
- National Biologics Facility (NBF)
- The University of Queensland
- Biointelect Venturer Funding: $1,500,000